Definium Therapeutics, Inc.
DFTX
株式のランク
#3484
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
株価
$35.98
時価総額
$4.83B
変化（1日）
1.39%
変化（1年）
239.49%
国
US
取引 Definium Therapeutics, Inc. (DFTX)
カテゴリー
Healthcare
Definium Therapeutics, Inc.（DFTX）の株価履歴
終値の最高値: $10.57 （2024-04-01）
終値の最安値: $4.87 （2020-03-01）
終値の最安値: $4.87 （2020-03-01）
Definium Therapeutics, Inc. の株価履歴（2020 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $535.81 | 25.65% |
US
|
|
| $188.41 | 601.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $890.95 | 9.43% |
NL
|
